Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. KBH
4. HON
5. HONA
6. TTWO
7. HELP
8. GDYN
9. NKE
10. MSCI

Go back to Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)

Ionis Pharmaceuticals (IONS) Misses Q3 EPS by 13c, Revenues Miss

November 4, 2020 7:06 AM EST

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.22), $0.13 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $160 million versus the consensus estimate of $182.14 million.

"We took an important step forward in our evolution when we acquired Akcea. This transaction supports our commercial strategy, further enabling us to maximize the value of our Ionis-owned pipeline. As one company, we believe we are stronger and more efficient, with an enhanced ability to... More